{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:23:12Z","timestamp":1769610192214,"version":"3.49.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) are rare indolent chronic B-cell lymphomas. Prognosis is typically good with median survival around 10-15 years. Management is generally based on the presence of symptoms or high tumor burden. There are no standard treatments for these 2 entities, and therapeutic strategies are rapidly evolving. Clinical developments for these 2 entities are oriented by genomic studies, with largely overlapping mutational profiles involving the NOTCH, B-cell receptor (BcR) and nuclear factor \u03baB (NF-\u03baB) signaling, chromatin remodeling, and the cytoskeleton. Although new therapeutic options based on targeting signaling pathways and overcoming resistance are increasingly available, few specific prospective studies are performed for these rare subtypes, limiting the conclusions that can be drawn. Novel drugs targeting B-cell signaling have shown promise, including ibrutinib and copanlisib. The second-generation oral immunomodalator (IMiD) lenalidomide showed impressive results when combined with rituximab. Other potential solutions include targeting the NF-\u03baB, JAK\/STAT, BCL2, NOTCH, and Toll-like receptor signaling pathways; however, studies in these 2 MZL entities are yet to prove a definitive benefit. Molecular profiling is now a cornerstone of diagnostic, prognostic, and therapeutic strategies to offer patient- and disease-specific solutions. The development of a wider range of effective targeted therapies and prognostic biomarkers is keenly awaited and is expected to strongly affect the natural history of SMZL and NMZL.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.371","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma"],"prefix":"10.1182","volume":"2017","author":[{"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[{"name":"Hemato-Oncology, H\u00f4pital Saint-Louis, Assistance Publique\u2014H\u00f4pitaux de Paris, Paris, France; Diderot University, Sorbonne Paris-Cit\u00e9, Paris, France; and EA7324, Descartes University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"20","key":"2019111707263231300_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111707263231300_B2","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111707263231300_B3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111707263231300_B4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111707263231300_B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111707263231300_B6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2013","journal-title":"Cancer"},{"key":"2019111707263231300_B7","article-title":"Splenic marginal zone lymphoma (SMZL) treated with rituximab (R) monotherapy: a long term follow-up study on 104 patients [abstract]","volume-title":"Haematologica","author":"Kalpadakis","year":"2017"},{"issue":"8","key":"2019111707263231300_B8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"9873","key":"2019111707263231300_B9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"2019111707263231300_B10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428194.2014.919636","article-title":"Splenic marginal-zone lymphoma: ontogeny and genetics","volume":"56","author":"Baliakas","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2019111707263231300_B11","article-title":"Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment [published online ahead of print 10 April 2017]","author":"Ghia","journal-title":"J Intern Med"},{"issue":"8","key":"2019111707263231300_B12","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/1078-0432.CCR-15-1170","article-title":"An immunogenetic signature of ongoing antigen interactions in splenic marginal zone lymphoma expressing IGHV1-2*04 receptors","volume":"22","author":"Bikos","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111707263231300_B13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111707263231300_B14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"2019111707263231300_B15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111707263231300_B16","doi-asserted-by":"crossref","first-page":"e44997","DOI":"10.1371\/journal.pone.0044997","article-title":"An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma","volume":"7","author":"Watkins","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2019111707263231300_B17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J Exp Med"},{"issue":"9","key":"2019111707263231300_B18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J Exp Med"},{"issue":"6","key":"2019111707263231300_B19","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Mart\u00ednez","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2019111707263231300_B20","doi-asserted-by":"crossref","first-page":"e83244","DOI":"10.1371\/journal.pone.0083244","article-title":"Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma","volume":"8","author":"Parry","year":"2013","journal-title":"PLoS One"},{"issue":"21","key":"2019111707263231300_B21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4247.4247","article-title":"Prognostic impact of somatic NOTCH2 mutation in splenic marginal zone lymphoma [abstract]","volume":"122","author":"Algrin","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111707263231300_B22","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2011-02-339556","article-title":"Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets","volume":"119","author":"Arribas","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111707263231300_B23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"2019111707263231300_B24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111707263231300_B25","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111707263231300_B26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2014.65","article-title":"Detection of MYD88 L265P in peripheral blood of patients with Waldenstr\u00f6m\u2019s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"28","author":"Xu","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"2019111707263231300_B27","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111707263231300_B28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111707263231300_B29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111707263231300_B30","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"2019111707263231300_B31","author":"Gaudio"},{"key":"2019111707263231300_B32","author":"Dreyling"},{"issue":"8","key":"2019111707263231300_B33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111707263231300_B34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"2019111707263231300_B35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111707263231300_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.705.705","article-title":"The coding genome of nodal marginal zone lymphoma reveals recurrent molecular alterations of PTPRD and other Jak\/Stat signaling genes [abstract]","volume":"124","author":"Spina","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111707263231300_B37","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/371\/1251350\/hem00052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/371\/1251350\/hem00052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:26:50Z","timestamp":1573975610000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/371\/21222\/Improved-biological-insight-and-influence-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.371","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}